Navigation Links
Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
Date:1/9/2012

GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development.

Dr. Onakunle will report directly to President and CEO, Dr. Igor Fisch and will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

"Selexis is experiencing a tremendous growth cycle by offering more innovation and long-term value to our customers. Yemi's wealth of business development and sales experience in biologics and cell line development will be instrumental in expanding the SUREtechnology Platform™ into important markets," said Dr. Igor Fisch, CEO of Selexis. "Yemi's understanding of our technology and expanding global customer base makes him an excellent choice for this newly created position."

Dr. Onakunle has over 15 years' experience in drug manufacturing and cell line development. Prior to working at Selexis, Dr. Onakunle was Director of Commercial Development at Diosynth RTP Inc. and Associate Director of Business Development at Lonza Custom Manufacturing – organizations providing process development and cGMP manufacturing services in mammalian production platforms. More recently, Dr. Onakunle was Head of Sales and Marketing at Bachem Americas Inc. - a contract manufacturing organization focusing on peptides and complex organic molecules. In these positions, he has a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Dr. Onakunle is a member of the Board of Directors of VLP Biotech Inc, a vaccine development company based in San Diego, CA and has been a Business Advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Dr. Onakunle holds a Ph.D. from the Unive
'/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. Selexis SA to Present at Biotech Showcase 2012
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Omeros Appoints David A. Mann to its Board of Directors
11. RainDance Technologies Appoints Olex Vice President, System Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... Inc. (NYSE: MDT ) has submitted ... and Drug Administration (FDA) for the use of ... system (including a newly developed catheter) for use ... delivered intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... 21 Startech,Environmental Corp. (OTC Bulletin Board: ... Company, announced today that the,EnviroSafe Industrial Services ... its original plans for its new recycling-facility ... to install three Plasma Converters Systems,purchased last ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that it has elected to suspend,enrolment in ... its Vascular Wrap,product candidate in patients undergoing surgery ... an imbalance of infections that have,been observed between ...
... A group of German,investors is about to acquire up ... purchasing price of up to EUR 750,000. The acquisition,will be ... subscribed,to by the investors. It will become effective after the ... and after the capital increase will,have been entered in the ...
Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Hospital Research Institute (OHRI) and the University of Ottawa have ... Spinal muscular atrophy (SMA), the leading inherited cause of death ... student Melissa Bowerman have found that an enzyme called RhoA ... and blocking this enzyme can greatly increase survival. The study ...
... 2010 Using a novel light activation technique, Scripps Research ... a modest ability to fight specific proteins into virtual protein ... capable of inactivating nearby proteins when triggered by light, could ... researchers with a new set of research tools and options. ...
... of psychopaths appear to be wired to keep seeking a ... The research uncovers the role of the brain,s reward system ... understanding what drives these individuals. "This study underscores ... Dr. Francis S. Collins, director of the National Institutes of ...
Cached Biology News:Study opens new avenue for developing treatments for genetic muscle-wasting disease 2Light activated 'warhead' turns modest molecules into super protein killers 2Light activated 'warhead' turns modest molecules into super protein killers 3Psychopaths' brains wired to seek rewards, no matter the consequences 2Psychopaths' brains wired to seek rewards, no matter the consequences 3
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... 384-well reaction module is used for nucleic ... with an interchangeable, 384-well reaction module (5-20 ... and control and ramp rates that are ... the iCycler base with 384-well reaction module, ...
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
Biology Products: